Trial Profile
A phase II open label study of the safety and efficacy of CC-5013 [lenalidomide] treatment for patients with myelodysplastic syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Nov 2019
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- Sponsors Celgene Corporation
- 06 Nov 2019 Status changed from active, no longer recruiting to completed.
- 24 Sep 2005 New trial record.